{
    "nct_id": "NCT03653247",
    "official_title": "A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 40 Years",
    "exclusion_criteria": "* Previous receipt of an autologous or allogeneic HSCT or solid organ transplantation\n* Previous treatment with gene therapy\n* Current enrollment in an interventional study or having received an investigational drug within 30 days of study enrollment\n* Pregnant or breastfeeding female\n* Female or male who plans to become pregnant or impregnate a partner, respectively, during the anticipated study period\n* Contraindication to plerixafor, apheresis, or busulfan\n* Treatment with prohibited medication in previous 30 days\n* Known allergy or hypersensitivity to plerixafor, busulfan, or investigational product excipients\n* History of active malignancy within past 5 years, any history of hematologic malignancy, or a family history of a cancer predisposition syndrome (without negative result of candidate)\n* Current diagnosis of uncontrolled seizures\n* History of significant bleeding disorder\n* Clinically significant infection\n* Any major organ dysfunction involving brain, kidney, liver, lung, or heart (e.g., congestive heart failure, pulmonary hypertension)\n* Corrected QT interval of more than 500 millisecond (ms) based on screening electrocardiogram (ECG)\n* Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)\n* Known to have a gamma-globin variant associated with altered oxygen affinity\n* Hereditary persistence of fetal hemoglobin (HPFH) or HbF concentration of more than or equal to 20 percent (%) at screening\n* Absolute Neutrophil Count (ANC) of less than or equal to 1,000 per microliter\n* Platelet count of less than 100,000 per microliter\n* History of platelet alloimmunization (precluding ability to provide transfusion support)\n* Extensive Red Blood Cell (RBC) alloimmunization (precluding ability to provide transfusion support)\n* Judged unsuitable for participation by investigator and/or sponsor",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* Ages 18 to 40\n* Confirmation of sickle cell disease (SCD) diagnosis (HbSS or HbS[beta]0 genotype)\n* Severe SCD, defined as having 1 or more of the following manifestations: Clinically significant neurologic event (example [e.g.], stroke) or any neurological deficit lasting more than 24 hours; History of 2 or more episodes or Acute Chest Syndrome (ACS) in 2 years prior to informed consent (despite adequate supportive therapies such as asthma therapy); Six or more pain crises per year in 2 years prior to informed consent (requiring intravenous [IV] pain management in the outpatient or inpatient hospital setting); History of 2 or more cases or priapism with participant seeking medical care in the 2-years prior to informed consent; Regular RBC transfusion therapy in the year prior to informed consent (having received 8 or more transfusions to prevent vaso-occlusive clinical complications); and Echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity of greater than or equal to 2.5 meter per second (m/s)\n* Clinically stable to undergo stem cell mobilization and myeloablative hematopoietic stem cell transplantation (HSCT)\n* Adequate physiological function, defined as the following: Karnofsky/Lansky Performance of greater than or equal to 60; Acceptable cardiac function as defined in protocol; Acceptable pulmonary function as defined in protocol; Acceptable renal function as defined in protocol; and Acceptable hepatic function as defined in protocol\n* Ability to understand purpose and risks of study, provide Informed Consent Form (ICF) and authorization to use protected health information\n* Completion of age-appropriate cancer screening\n* Willingness to use double-barrier method of contraception through entire study period (for participants of childbearing potential)\n* Willingness to receive blood transfusions\n* Willingness to discontinue hydroxyurea (HU) at least 30 days prior to stem cell mobilization through Day 100 post-transplantation"
}